COVID-19
Here’s a look at the latest Long COVID research and the reemergence of a therapy whose efficacy has yet to be proven.
WHO declared the monkeypox outbreak a “public health emergency of international concern [PHEIC].” As COVID-19 wanes, Tonix, SIGA, Emergent Bio and others are now targeting monkeypox.
Here’s a look at global biopharma company news stories including Rona Therapeutics, Genuine Bio and NEOsphere Bio.
“The applications for mRNA are quite broad, because, basically, you are giving information to a cell to make any protein you want,” CureVac CFO Pierre Kemula told BioSpace.
Researchers evaluate just how well therapeutic antibodies and antivirals work against Omicron, Vaxart’s oral vaccine shows early promise and hypertension doubles the risk of hospitalization.
The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here’s a look at recent biopharma patent disputes.
As the BA.4/BA.5 Omicron subvariants spread, researchers continue to develop COVID-19 therapies and approaches for preventing or treating the disease. For that and more, continue reading.
The FDA granted Novavax’s COVID-19 vaccine Emergency Use Authorization after a lengthy and obstacle-riddled journey. It is authorized as a two-dose primary series for adults 18 years and older.
Aviv Clinics reported data from a study that suggests hyperbaric oxygen therapy may alleviate long COVID symptoms, particularly those associated with cognition.
An NIH-sponsored trial assessing a combination of Humanigen’s lenzilumab and Gilead Sciences’ remdesivir in hospitalized COVID-19 patients failed to achieve the primary endpoint.
PRESS RELEASES